DNA Brands, Inc.
DNAX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | -0.33 | 0.99 |
| FCF Yield | -2.28% | 0.00% | -20.24% | -1.44% |
| EV / EBITDA | -14.35 | -21.62 | -12.69 | -107.04 |
| Quality | ||||
| ROIC | 13.64% | 51.16% | 89.44% | -58.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 99.23% |
| Cash Conversion Ratio | 0.02 | 1.12 | 1.43 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 194.04% |
| Free Cash Flow Growth | 0.00% | 0.00% | 3.04% | 60.34% |
| Safety | ||||
| Net Debt / EBITDA | -12.24 | -18.49 | -6.53 | -6.48 |
| Interest Coverage | -0.92 | -0.53 | -11.27 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -11,135.19 |